SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/13/17 Idt Corp 10-Q 1/31/17 68:3.8M Edgar Agents LLC/FA |
Document/Exhibit Description Pages Size 1: 10-Q Quarterly Report HTML 382K 2: EX-31.1 Certification -- §302 - SOA'02 HTML 23K 3: EX-31.2 Certification -- §302 - SOA'02 HTML 23K 4: EX-32.1 Certification -- §906 - SOA'02 HTML 19K 5: EX-32.2 Certification -- §906 - SOA'02 HTML 19K 12: R1 Document and Entity Information HTML 39K 13: R2 Consolidated Balance Sheets HTML 125K 14: R3 Consolidated Balance Sheets (Parenthetical) HTML 42K 15: R4 Consolidated Statements of Income (Unaudited) HTML 80K 16: R5 Consolidated Statements of Comprehensive Income HTML 44K (Unaudited) 17: R6 Consolidated Statements of Cash Flows (Unaudited) HTML 117K 18: R7 Basis of Presentation HTML 24K 19: R8 Zedge Spin-Off HTML 31K 20: R9 Investment in Cornerstone Pharmaceuticals, Inc. HTML 30K 21: R10 Marketable Securities HTML 59K 22: R11 Fair Value Measurements HTML 40K 23: R12 Derivative Instruments HTML 35K 24: R13 Equity HTML 47K 25: R14 Earnings Per Share HTML 36K 26: R15 Revolving Credit Loan Payable HTML 24K 27: R16 Accrued Severance Expense HTML 21K 28: R17 Accumulated Other Comprehensive Loss HTML 32K 29: R18 Business Segment Information HTML 51K 30: R19 Commitments and Contingencies HTML 41K 31: R20 Other (Expense) Income, Net HTML 28K 32: R21 Income Taxes HTML 23K 33: R22 Recently Issued Accounting Standard Not Yet HTML 32K Adopted 34: R23 Zedge Spin-Off (Tables) HTML 26K 35: R24 Marketable Securities (Tables) HTML 87K 36: R25 Fair Value Measurements (Tables) HTML 36K 37: R26 Derivative Instruments (Tables) HTML 25K 38: R27 Equity (Tables) HTML 40K 39: R28 Earnings Per Share (Tables) HTML 45K 40: R29 Accumulated Other Comprehensive Loss (Tables) HTML 27K 41: R30 Business Segment Information (Tables) HTML 60K 42: R31 Commitments and Contingencies (Tables) HTML 28K 43: R32 Other (Expense) Income, Net (Tables) HTML 31K 44: R33 Zedge Spin-Off (Details) HTML 27K 45: R34 Investment in Cornerstone Pharmaceuticals, Inc. HTML 87K (Details) 46: R35 Marketable Securities (Details) HTML 64K 47: R36 Marketable Securities (Details 1) HTML 34K 48: R37 Marketable Securities (Details 2) HTML 44K 49: R38 Marketable Securities (Details Textual) HTML 38K 50: R39 Fair Value Measurements (Details) HTML 30K 51: R40 Fair Value Measurements (Details Textual) HTML 22K 52: R41 Derivative Instruments (Details) HTML 21K 53: R42 Equity (Details) HTML 62K 54: R43 Equity (Details Textual) HTML 60K 55: R44 Earnings Per Share (Details) HTML 33K 56: R45 Earnings Per Share (Details 1) HTML 22K 57: R46 Revolving Credit Loan Payable (Details) HTML 46K 58: R47 Accrued Severance Expense (Details) HTML 26K 59: R48 Accumulated Other Comprehensive Loss (Details) HTML 48K 60: R49 Business Segment Information (Details) HTML 42K 61: R50 Business Segment Information (Details Textual) HTML 20K 62: R51 Commitments and Contingencies (Details) HTML 28K 63: R52 Commitments and Contingencies (Details Textual) HTML 40K 64: R53 Other (Expense) Income, Net (Details) HTML 33K 65: R54 Income Taxes (Details) HTML 24K 67: XML IDEA XML File -- Filing Summary XML 117K 66: EXCEL IDEA Workbook of Financial Reports XLSX 61K 6: EX-101.INS XBRL Instance -- idt-20170131 XML 1.04M 8: EX-101.CAL XBRL Calculations -- idt-20170131_cal XML 137K 9: EX-101.DEF XBRL Definitions -- idt-20170131_def XML 382K 10: EX-101.LAB XBRL Labels -- idt-20170131_lab XML 931K 11: EX-101.PRE XBRL Presentations -- idt-20170131_pre XML 600K 7: EX-101.SCH XBRL Schema -- idt-20170131 XSD 127K 68: ZIP XBRL Zipped Folder -- 0001213900-17-002245-xbrl Zip 100K
EXHIBIT 32.2
Certification
Pursuant to
18 U.S.C. Section 1350
(as Adopted Pursuant to Section 906 of
the Sarbanes-Oxley Act Of 2002)
In connection with the Quarterly Report of IDT Corporation (the “Company”) on Form 10-Q for the quarter ended January 31, 2017 as filed with the Securities and Exchange Commission (the “Report”), I, Marcelo Fischer, Senior Vice President of Finance of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: March 13, 2017 | /s/ MArcelo Fischer |
Marcelo Fischer Senior Vice President of Finance (Principal Financial Officer) |
A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to IDT Corporation and will be retained by IDT Corporation and furnished to the Securities and Exchange Commission or its staff upon request.
This ‘10-Q’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on: | 3/13/17 | None on these Dates | ||
For Period end: | 1/31/17 | |||
List all Filings |